Company Overview and News

3
Sluggish Results And Guidance Renew Questions About BB&T's Self-Improvement

2018-07-20 seekingalpha
Weak growth and weaker guidance from BB&T leave a sour taste, and the market is worried BB&T will divert capital from buybacks toward M&A.
BBT STT STT.PRC CMA STT.PRE STT.PRD STT.PRG

4
Texas Capital's Strong Loan Growth And Spread Leverage Is A Potent Growth Cocktail

2018-07-20 seekingalpha
Exceptional asset sensitivity and loan growth are generating strong revenue and operating income growth for this Texas-based commercial lender.
WFC WFCNP WFC.WS CMA TCBI WFC.PRL TCBIL WFC.PRJ WFC.PRT WFC.PRR TCBIW WFC.PRQ WFC.PRP WFC.PRO TCBIP WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

4
State Street (STT) Beats on Q2 Earnings, to Acquire CRD

2018-07-20 zacks
State Street’s (STT - Free Report) second-quarter 2018 adjusted earnings of $2.05 per share outpaced the Zacks Consensus Estimate of $2.01. Results excluded $77 million or 17 cents per share of repositioning charge related to organizational realignment. State Street’s shares lost more than 5% in pre-market trading. Suspension of share buybacks till the end of this year due to the announcement of deal to acquire Charles River Development (“CRD”) is perhaps the primary reason.
BBT STT STT.PRC CMA STT.PRE STT.PRD STT.PRG KEY

9
SunTrust (STI) Q2 Earnings Beat Estimates, Revenues Improve

2018-07-20 zacks
SunTrust Banks' (STI - Free Report) second-quarter 2018 earnings of $1.49 per share outpaced the Zacks Consensus Estimate of $1.30. Also, the figure compared favorably with the prior-year quarter’s earnings of $1.03. Results were primarily driven by rise in revenues as well as lower provisions. Also, an improvement in overall asset quality was a tailwind. However, higher expenses hurt results to some extent.
STI.WS.B STI.WS.A C CMA PNC.PRP PNC.PRQ PNCFO PNC.WS STI PNC STI-A PNUCL STI.PRE

1
KeyCorp (KEY) Q2 Earnings Beat, Fee Income & Expenses Rise

2018-07-19 zacks
KeyCorp’s (KEY - Free Report) second-quarter 2018 earnings of 44 cents per share surpassed the Zacks Consensus Estimate of 42 cents. Also, this compared favorably with earnings of 36 cents recorded in the prior-year quarter. Shares of KeyCorp have gained almost 2% in pre-market trading. Notably, the stock’s price performance after the full day’s trading will give a better indication about investors’ sentiments.
STI.WS.B STI.WS.A STI CMA STI-A STI.PRE KEY

4
A Sour Sentiment Toward First Horizon Could Mean Opportunity

2018-07-19 seekingalpha
First Horizon's second quarter results were roundly disappointing, with weaker core interest income, very weak trading results, and higher than expected expenses.
WFC WFCNP WFC.WS CMA WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

4
BancorpSouth's (BXS) Q2 Earnings Beat on Higher Revenues

2018-07-19 zacks
BancorpSouth (BXS - Free Report) reported second-quarter 2018 operating earnings of 56 cents per share, beating the Zacks Consensus Estimate by a penny. Also, the bottom line compared favorably with the year-ago quarter earnings of 41 cents.
CMA FHN FHN.PRA BXS

11
BB&T (BBT) Posts In-Line Earnings in Q2, Provisions Stable

2018-07-19 zacks
BB&T Corporation’s (BBT - Free Report) second-quarter 2018 adjusted earnings of $1.01 was in-line with the Zacks Consensus Estimate. Moreover, the figure recorded 29.5% surge from the year-ago quarter. Results reflected slight rise in revenues and lower operating expenses. Also, the balance sheet position remained strong during the quarter under review. Further, stable provisions supported results to some extent.
BBT PNC.WS C CMA PNC.PRP PNC PNC.PRQ PNUCL PNCFO

4
Exceptional Rate Leverage Continues To Drive Comerica

2018-07-19 seekingalpha
Comerica once again delivered strong NIM leverage even though loan and balance sheet growth remain lackluster.
WFC WFCNP WFC.WS CMA WFC.PRL WFC.PRJ WFC.PRT OZK WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

50
PNC Financial Is A Great Bank With A Good Valuation In A So-So Market

2018-07-18 seekingalpha
PNC posts a modest beat in the second quarter, with a Goldilocks combination of loan growth, spread improvement, and cost leverage.
WFC WFCNP WFC.WS CMA WFC.PRL WFC.PRJ BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

7
5 Major Bank Stocks Set to Outpace Earnings Estimates in Q2

2018-07-17 investorplace
The earnings season is knocking at the door and investors are keen to see how major banks have performed in the second quarter amid uncertainty related to the trade war fears.
STI.WS.B STI.WS.A STI JPM CMA STI-A MTB STI.PRE KEY

0
Comerica Inc. (CMA) CEO Ralph Babb on Q2 2018 Results - Earnings Call Transcript

2018-07-17 seekingalpha
Good morning. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Comerica Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].
CMA.WS DB MS.PRI CMA MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA CMPWW

9
Comerica (CMA) Q2 Earnings Improve Y/Y, Revenues Increase

2018-07-17 zacks
Comerica (CMA - Free Report) reported adjusted earnings per share of $1.90 in second-quarter 2018, up from the year-ago adjusted figure of $1.15. Including certain non-recurring items, earnings came in at $1.87. The Zacks Consensus Estimate was $1.62.
WFC WFCNP WFC.WS C CMA WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY 3772 WFC.PRX WFC.PRW WFC.PRV

0
Comerica Inc. 2018 Q2 - Results - Earnings Call Slides

2018-07-17 seekingalpha
The following slide deck was published by Comerica Inc. in conjunction with their 2018 Q2 earnings call.
CMA.WS CMA CMPWW

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CMA / Comerica, Inc. on message board site Silicon Investor.

PCCM PACIFIC CMA General Communication, Inc. GNCMA
musicmaker.com, Inc. (HITS) FMA / FracMaster
Cream Minerals DEBIQ - If Debbie Reynolds Married Vince McMahon...
CREAM MINERALS CMA.V CMAG - Casino Magic
CASINO MAGIC! (CMAG) 7 HOLDINGS AND GROWING STRONG! General Communications Cl A (GNCMA)
CUSIP: 200340107